Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.2M
Short interest
settlement 2026-10-15
7.2
Days to cover
-2.5 days vs prior
32.8%
Short share of volume
2026-10-28
3
Fails to deliver
settlement 2026-09-15
Tue 3 Nov
Next earnings
estimated date
-$6.6M
Insider flow, 90 days
0 buys, 25 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in MDGL is 2,194,545 shares, down 59,878 shares over the last month. Over the last 48 readings it ranged from 1,965,849 shares (31 July 2026) to 4,734,136 shares (13 December 2024). The latest reading sits at the bottom of that range. At the reported average volume of 303K shares a day that is 7.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mdgl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,194,545 | -8.4% | 303,113 | 7.24 |
| 2026-09-30 | 2,396,369 | +6.3% | 245,001 | 9.78 |
| 2026-09-15 | 2,254,423 | +0.6% | 197,439 | 11.42 |
| 2026-08-31 | 2,240,575 | +10.6% | 236,743 | 9.46 |
| 2026-08-14 | 2,025,404 | +3.0% | 335,012 | 6.05 |
| 2026-07-31 | 1,965,849 | -4.7% | 406,250 | 4.84 |
| 2026-07-15 | 2,062,862 | -41.5% | 297,279 | 6.94 |
| 2026-06-30 | 3,526,539 | -6.7% | 568,813 | 6.20 |
| 2026-06-15 | 3,780,568 | -1.1% | 263,958 | 14.32 |
| 2026-05-29 | 3,823,127 | -1.9% | 271,574 | 14.08 |
| 2026-05-15 | 3,897,454 | +1.1% | 316,164 | 12.33 |
| 2026-04-30 | 3,854,441 | -4.0% | 233,959 | 16.47 |
| 2026-04-15 | 4,012,756 | +2.6% | 316,338 | 12.69 |
| 2026-03-31 | 3,909,299 | -0.5% | 428,791 | 9.12 |
| 2026-03-13 | 3,929,986 | +5.0% | 282,168 | 13.93 |
| 2026-02-27 | 3,742,574 | +3.4% | 458,810 | 8.16 |
| 2026-02-13 | 3,619,351 | -9.1% | 326,736 | 11.08 |
| 2026-01-30 | 3,983,413 | +3.2% | 313,931 | 12.69 |
| 2026-01-15 | 3,858,573 | +4.0% | 395,033 | 9.77 |
| 2025-12-31 | 3,710,257 | -0.2% | 283,918 | 13.07 |
| 2025-12-15 | 3,718,220 | -0.1% | 265,042 | 14.03 |
| 2025-11-28 | 3,721,183 | -1.7% | 373,543 | 9.96 |
| 2025-11-14 | 3,786,197 | +1.4% | 512,811 | 7.38 |
| 2025-10-31 | 3,735,127 | +1.3% | 294,823 | 12.67 |
| 2025-10-15 | 3,687,958 | -0.9% | 264,501 | 13.94 |
| 2025-09-30 | 3,723,137 | -10.0% | 342,191 | 10.88 |
| 2025-09-15 | 4,137,397 | +2.2% | 324,579 | 12.75 |
| 2025-08-29 | 4,046,651 | +6.7% | 435,511 | 9.29 |
| 2025-08-15 | 3,793,843 | -4.7% | 454,038 | 8.36 |
| 2025-07-31 | 3,980,199 | +5.1% | 450,798 | 8.83 |
| 2025-07-15 | 3,787,367 | -4.5% | 236,184 | 16.04 |
| 2025-06-30 | 3,966,696 | -4.5% | 325,607 | 12.18 |
| 2025-06-13 | 4,152,509 | +6.9% | 299,276 | 13.88 |
| 2025-05-30 | 3,885,358 | -2.9% | 321,652 | 12.08 |
| 2025-05-15 | 4,000,742 | -2.5% | 387,419 | 10.33 |
| 2025-04-30 | 4,104,430 | +1.9% | 359,109 | 11.43 |
| 2025-04-15 | 4,027,147 | +0.7% | 349,950 | 11.51 |
| 2025-03-31 | 3,997,671 | -2.4% | 235,748 | 16.96 |
| 2025-03-14 | 4,094,246 | +9.1% | 479,995 | 8.53 |
| 2025-02-28 | 3,753,213 | -1.1% | 431,065 | 8.71 |
| 2025-02-14 | 3,795,295 | -4.7% | 354,573 | 10.70 |
| 2025-01-31 | 3,982,712 | -2.5% | 465,120 | 8.56 |
| 2025-01-15 | 4,083,736 | -0.6% | 454,640 | 8.98 |
| 2024-12-31 | 4,106,529 | -13.3% | 325,210 | 12.63 |
| 2024-12-13 | 4,734,136 | +10.6% | 295,218 | 16.04 |
| 2024-11-29 | 4,281,332 | -3.5% | 377,901 | 11.33 |
| 2024-11-15 | 4,434,650 | -2.2% | 819,575 | 5.41 |
| 2024-10-31 | 4,532,914 | +11.9% | 362,617 | 12.50 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of MDGL volume is 32.8%, down 27.9 points over the last five sessions. Over the last 30 readings it ranged from 29.7% (12 October 2026) to 69.7% (18 September 2026). The latest reading sits at the bottom of that range. The latest reading is 16.8 points below the 30-session average of 49.6%, on 125K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 41K | 125K | 32.8% | 639 |
| 2026-10-27 | 40K | 93K | 42.7% | 0 |
| 2026-10-26 | 47K | 114K | 40.7% | 1 |
| 2026-10-23 | 40K | 94K | 42.8% | 0 |
| 2026-10-22 | 37K | 89K | 41.2% | 0 |
| 2026-10-21 | 80K | 132K | 60.6% | 0 |
| 2026-10-20 | 87K | 171K | 50.8% | 0 |
| 2026-10-19 | 47K | 96K | 49.1% | 0 |
| 2026-10-16 | 91K | 153K | 59.2% | 0 |
| 2026-10-15 | 59K | 126K | 46.7% | 0 |
| 2026-10-14 | 81K | 159K | 50.7% | 1,532 |
| 2026-10-13 | 56K | 128K | 43.6% | 0 |
| 2026-10-12 | 76K | 255K | 29.7% | 0 |
| 2026-10-09 | 73K | 143K | 51.1% | 0 |
| 2026-10-08 | 63K | 156K | 40.0% | 0 |
| 2026-10-07 | 50K | 108K | 46.8% | 0 |
| 2026-10-06 | 65K | 157K | 41.3% | 0 |
| 2026-10-05 | 29K | 95K | 30.7% | 6 |
| 2026-10-02 | 57K | 125K | 45.2% | 0 |
| 2026-10-01 | 55K | 94K | 58.3% | 0 |
| 2026-09-30 | 54K | 106K | 50.6% | 0 |
| 2026-09-29 | 63K | 110K | 57.2% | 1 |
| 2026-09-28 | 79K | 158K | 50.1% | 14,272 |
| 2026-09-25 | 35K | 62K | 56.2% | 0 |
| 2026-09-24 | 60K | 97K | 62.3% | 8 |
| 2026-09-23 | 84K | 130K | 64.5% | 0 |
| 2026-09-22 | 64K | 97K | 66.5% | 40 |
| 2026-09-21 | 49K | 87K | 56.3% | 0 |
| 2026-09-18 | 44K | 63K | 69.7% | 528 |
| 2026-09-17 | 32K | 65K | 49.7% | 22 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 15 September 2026, the fails-to-deliver balance in MDGL is 3 shares, down 1,162 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (15 September 2026) to 208,700 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-15 | 3 | $540.06 | $2K |
| 2026-08-28 | 1,165 | $543.69 | $633K |
| 2026-08-20 | 253 | $540.16 | $137K |
| 2026-08-18 | 22 | $524.87 | $12K |
| 2026-08-12 | 21 | $535.27 | $11K |
| 2026-08-10 | 3,620 | $510.04 | $1.8M |
| 2026-08-04 | 17,959 | $482.00 | $8.7M |
| 2026-08-03 | 248 | $467.32 | $116K |
| 2026-07-27 | 143 | $544.51 | $78K |
| 2026-07-20 | 49 | $553.48 | $27K |
| 2026-07-10 | 6,215 | $560.01 | $3.5M |
| 2026-07-08 | 1,670 | $545.36 | $911K |
| 2026-06-30 | 208,494 | $527.28 | $109.9M |
| 2026-06-29 | 208,700 | $512.65 | $107.0M |
| 2026-06-26 | 2,145 | $513.79 | $1.1M |
| 2026-06-15 | 2,426 | $480.77 | $1.2M |
| 2026-06-12 | 5,930 | $474.28 | $2.8M |
| 2026-06-08 | 1,997 | $486.98 | $972K |
| 2026-06-05 | 363 | $492.83 | $179K |
| 2026-05-26 | 268 | $517.26 | $139K |
| 2026-05-14 | 97 | $518.87 | $50K |
| 2026-04-21 | 243 | $527.11 | $128K |
| 2026-04-07 | 4,628 | $533.88 | $2.5M |
| 2026-04-02 | 158 | $529.84 | $84K |
| 2026-03-27 | 524 | $518.76 | $272K |
| 2026-03-26 | 373 | $461.93 | $172K |
| 2026-03-25 | 118 | $445.04 | $53K |
| 2026-03-23 | 539 | $441.16 | $238K |
| 2026-03-20 | 149 | $454.22 | $68K |
| 2026-03-13 | 4 | $438.73 | $2K |
Insider trades
SEC Form 4, newest first. JSONInsiders at MDGL reported 25 open-market sells worth $6.6M in the last 90 days and no open-market buys. Latest filing: Sibold William John (President and CEO) on 2026-09-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Sibold William John | President and CEO | Sell | 120 | $546.38 | $66K | 198K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 761 | $544.83 | $415K | 198K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 2K | $544.02 | $837K | 199K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 1K | $542.60 | $652K | 200K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 368 | $541.64 | $199K | 201K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 687 | $540.59 | $371K | 202K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 160 | $537.62 | $86K | 202K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 218 | $535.94 | $117K | 203K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 106 | $534.06 | $57K | 203K |
| 2026-09-11 | Sibold William John | President and CEO | Sell | 60 | $533.09 | $32K | 203K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 160 | $542.55 | $87K | 203K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 362 | $541.65 | $196K | 203K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 505 | $540.19 | $273K | 203K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 215 | $539.03 | $116K | 204K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 520 | $538.30 | $280K | 204K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 640 | $537.17 | $344K | 205K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 1K | $536.11 | $558K | 205K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 644 | $535.27 | $345K | 206K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 396 | $534.20 | $212K | 207K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 512 | $533.09 | $273K | 207K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 368 | $531.99 | $196K | 208K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 522 | $530.23 | $277K | 208K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 347 | $529.27 | $184K | 209K |
| 2026-09-09 | Sibold William John | President and CEO | Sell | 131 | $527.88 | $69K | 209K |
| 2026-08-17 | Kelley Shannon T | General Counsel | Sell | 664 | $514.97 | $342K | 11K |
| 2026-08-15 | REED JOHN C | Director | Grant | 647 | $0.00 | $0 | 647 |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 280 | $555.05 | $155K | 209K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 1 | $550.72 | $551 | 210K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 153 | $550.01 | $84K | 210K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 47 | $548.87 | $26K | 210K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 680 | $547.70 | $372K | 210K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 269 | $547.08 | $147K | 210K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 275 | $545.71 | $150K | 211K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 545 | $544.71 | $297K | 211K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 110 | $543.79 | $60K | 212K |
| 2026-07-20 | Sibold William John | President and CEO | Sell | 140 | $542.75 | $76K | 212K |
| 2026-07-17 | Sibold William John | President and CEO | Exercise or conversion | 50K | price not stated in the filing | not stated | 212K |
| 2026-06-17 | Baker Brothers Life Sciences LP | Director | Grant | 908 | $0.00 | $0 | 204K |
| 2026-06-17 | Brennan Daniel J. | Director | Grant | 404 | $0.00 | $0 | 1K |
| 2026-06-17 | Daly James M | Director | Grant | 454 | $0.00 | $0 | 3K |
| 2026-06-17 | FOUSE JACQUALYN A | Director | Grant | 454 | $0.00 | $0 | 2K |
| 2026-06-17 | Levy Richard S | Director | Grant | 454 | $0.00 | $0 | 22K |
| 2026-06-17 | Taub Rebecca | Director | Grant | 454 | $0.00 | $0 | 453K |
| 2026-06-17 | BAKER BROS. ADVISORS LP | Director | Grant | 908 | $0.00 | $0 | 204K |
| 2026-06-01 | Soergel David | Chief Medical Officer | Sell | 1K | $495.74 | $517K | 10K |
| 2026-05-22 | Levy Richard S | Director | Sell | 40 | $512.97 | $21K | 26K |
| 2026-05-22 | Levy Richard S | Director | Sell | 80 | $519.98 | $42K | 22K |
| 2026-05-22 | Levy Richard S | Director | Sell | 782 | $518.76 | $406K | 22K |
| 2026-05-22 | Levy Richard S | Director | Sell | 1K | $517.59 | $775K | 23K |
| 2026-05-22 | Levy Richard S | Director | Sell | 723 | $516.87 | $374K | 24K |
| 2026-05-22 | Levy Richard S | Director | Sell | 657 | $515.92 | $339K | 25K |
| 2026-05-22 | Levy Richard S | Director | Sell | 343 | $514.67 | $177K | 26K |
| 2026-05-22 | Levy Richard S | Director | Sell | 439 | $512.50 | $225K | 26K |
| 2026-05-22 | Levy Richard S | Director | Sell | 610 | $511.40 | $312K | 27K |
| 2026-05-22 | Levy Richard S | Director | Sell | 151 | $510.36 | $77K | 27K |
| 2026-05-22 | Levy Richard S | Director | Sell | 320 | $508.24 | $163K | 27K |
| 2026-05-22 | Levy Richard S | Director | Sell | 40 | $506.68 | $20K | 28K |
| 2026-05-18 | Soergel David | Chief Medical Officer | Sell | 844 | $515.90 | $435K | 11K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 40 | $437.65 | $18K | 12K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 80 | $436.69 | $35K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 80 | $435.31 | $35K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 160 | $434.20 | $69K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 40 | $429.58 | $17K | 13K |
| 2026-03-06 | Sibold William John | President and CEO | Sell | 2K | $431.94 | $718K | 162K |
| 2026-03-06 | Taub Rebecca | Director | Sell | 491 | $431.94 | $212K | 452K |
| 2026-03-06 | Kelley Shannon T | General Counsel | Sell | 360 | $431.94 | $155K | 12K |
| 2026-03-06 | Huntsman Carole | Chief Commercial Officer | Sell | 419 | $431.94 | $181K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 116 | $432.56 | $50K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 120 | $430.90 | $52K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 160 | $429.00 | $69K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 80 | $427.85 | $34K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 420 | $426.86 | $179K | 13K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 40 | $425.08 | $17K | 14K |
| 2026-03-06 | Dier Mardi | EVP and CFO | Sell | 646 | $431.94 | $279K | 14K |
| 2026-03-04 | Sibold William John | President and CEO | Grant | 15K | $0.00 | $0 | 163K |
| 2026-03-04 | Soergel David | Chief Medical Officer | Grant | 4K | $0.00 | $0 | 12K |
| 2026-03-04 | Kelley Shannon T | General Counsel | Grant | 4K | $0.00 | $0 | 12K |
| 2026-03-04 | Huntsman Carole | Chief Commercial Officer | Grant | 4K | $0.00 | $0 | 13K |
| 2026-03-04 | Dier Mardi | EVP and CFO | Grant | 5K | $0.00 | $0 | 14K |
| 2026-03-02 | Dier Mardi | EVP and CFO | Sell | 1K | $427.21 | $505K | 9K |
| 2026-02-23 | Levy Richard S | Director | Exercise or conversion | 3K | $7.36 | $18K | 28K |
| 2026-01-26 | Sibold William John | President and CEO | Sell | 2K | $492.42 | $777K | 148K |
| 2026-01-26 | Taub Rebecca | Director | Sell | 647 | $492.42 | $319K | 453K |
| 2026-01-26 | Levy Richard S | Director | Exercise or conversion | 4K | $16.46 | $66K | 25K |
| 2026-01-26 | Huntsman Carole | Chief Commercial Officer | Sell | 570 | $494.59 | $282K | 9K |
| 2026-01-26 | Huntsman Carole | Chief Commercial Officer | Sell | 340 | $492.42 | $167K | 10K |
| 2026-01-20 | Taub Rebecca | Director | Sell | 2K | $490.77 | $1.1M | 453K |
| 2026-01-20 | Kelley Shannon T | General Counsel | Sell | 429 | $501.40 | $215K | 8K |
| 2026-01-20 | Kelley Shannon T | General Counsel | Sell | 263 | $490.77 | $129K | 9K |
| 2026-01-15 | Thakkar Rita | Chief Accounting Officer | Grant | 2K | $0.00 | $0 | 2K |
| 2026-01-09 | FRIEDMAN PAUL A | Director | Sell | 80 | $537.85 | $43K | 188K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 400 | $542.72 | $217K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 40 | $540.26 | $22K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 40 | $537.84 | $22K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 960 | $513.12 | $493K | 472K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 200 | $551.24 | $110K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 40 | $545.79 | $22K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Exercise or conversion | 240 | $15.80 | $4K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 400 | $539.26 | $216K | 456K |
| 2026-01-09 | Taub Rebecca | Director | Sell | 385 | $536.88 | $207K | 456K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON26 Form 144 notices on file for MDGL worth $102.7M at the prices reported; 2 in the last 90 days worth $28.6M. Latest: PAUL FRIEDMAN filed on 2026-09-28 to sell 50,000 shares ($25.8M) from 2026-09-28.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-28 | PAUL FRIEDMANDirector | 50K | $25.8M | 0.216% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-11 | WILLIAM SIBOLDDirector, Officer | 5K | $2.8M | 0.023% | 2026-09-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | DAVID SOERGELOfficer | 1K | $518K | 0.005% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-22 | RICHARD LEVYDirector | 6K | $2.9M | 0.025% | 2026-05-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | William SiboldOfficer and Director | 2K | $731K | 0.007% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | Rebecca TaubDirector | 491 | $216K | 0.002% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | Shannon KelleyOfficer | 360 | $158K | 0.002% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | Carole HuntsmanOfficer | 419 | $184K | 0.002% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | MARDI DIEROfficer | 1K | $587K | 0.006% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-06 | Mardi DierOfficer | 646 | $284K | 0.003% | 2026-03-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | Mardi DierOfficer | 1K | $511K | 0.005% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | William SiboldOfficer and Director | 2K | $758K | 0.007% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | Rebecca TaubDirector | 647 | $311K | 0.003% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | CAROLE A HUNTSMANOfficer | 570 | $274K | 0.003% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | Carole HuntsmanOfficer | 340 | $163K | 0.001% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | Rebecca TaubDirector | 2K | $1.1M | 0.010% | 2026-01-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | SHANNON KELLEYOfficer | 429 | $215K | 0.002% | 2026-01-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | Shannon KelleyOfficer | 263 | $132K | 0.001% | 2026-01-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-09 | REBECCA A TAUBDirector | 19K | $10.4M | 0.082% | 2026-01-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-10 | REBECCA A TAUBDirector | 19K | $10.3M | 0.082% | 2025-12-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-10 | PAUL FRIEDMANDirector | 50K | $27.5M | 0.218% | 2025-12-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | William John SiboldOfficer and Director | 2K | $1.4M | 0.011% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-02 | MARDI C DIEROfficer | 4K | $2.4M | 0.018% | 2025-12-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | Carole HuntsmanOfficer | 894 | $485K | 0.004% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | RICHARD S LEVYDirector | 9K | $4.5M | 0.037% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-05 | KENNETH M BATEDirector | 17K | $8.0M | 0.073% | 2025-11-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of MDGL in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is JANUS HENDERSON GROUP PLC at 8.8% of the class (2,018,647 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-29 | 13G/Ano. 4 | BlackRock, Inc.parent holding company | 1.1M | 4.6% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 9 | JANUS HENDERSON GROUP PLCparent holding company | 2.0M | 8.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | PAULSON & CO. INC.investment adviser | 1.4M | 6.1% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-12-12 | 13D/Ano. 2 | Rebecca Taub, M.D.individual | 1.8M | 7.8% | 2025-12-10 |
| 2025-12-12 | 13D/Ano. 2 | Paul A Friedman, M.D.individual | 1.8M | 7.8% | 2025-12-10 |
13F holders
Tracked managers holding MDGL at their latest 13F. JSON8 of the 30 tracked managers held MDGL at their latest 13F, $1.16B in total at quarter-end prices. Paulson & Co. is the largest at $719.5M (27.9% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Paulson & Co. | 2026-06-30 | 1.3M | $719.5M | 27.94% | -52K |
| Citadel Advisors | 2026-06-30 | 507K | $272.4M | 0.03% | +53K |
| Point72 Asset Management | 2026-06-30 | 137K | $73.6M | 0.08% | -88K |
| Millennium Management | 2026-06-30 | 81K | $43.6M | 0.02% | +40K |
| Renaissance Technologies | 2026-06-30 | 46K | $24.7M | 0.03% | -26K |
| D. E. Shaw & Co. | 2026-06-30 | 35K | $18.8M | 0.01% | +5K |
| AQR Capital Management | 2026-06-30 | 16K | $8.5M | 0.00% | -126 |
| Two Sigma Investments | 2026-06-30 | 566 | $304K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Madrigal Pharmaceuticals reported revenue of $364.3M, up 71.2% from the same quarter a year earlier, and net loss of $57.9M (-1.99 diluted EPS). In FY 2025 it generated -$189.6M of operating cash flow. As of 2026-06-30, cash was $292.7M against $340.8M of debt.
- Cash
- $292.7M
- Debt
- $340.8M
- Equity
- $523.7M
- Total assets
- $1.24B
- Shares outstanding
- 23,104,126
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $364.3M | -$57.9M | -15.9% | -1.99 |
| Q1 FY 2026 | 2026-03-31 | $311.3M | -$94.4M | -30.3% | -3.25 |
| Q4 FY 2025derived | 2025-12-31 | $321.1M | -$58.6M | -18.2% | n/a |
| Q3 FY 2025 | 2025-09-30 | $287.3M | -$114.2M | -39.8% | -4.01 |
| Q2 FY 2025 | 2025-06-30 | $212.8M | -$42.3M | -19.9% | -1.50 |
| Q1 FY 2025 | 2025-03-31 | $137.3M | -$73.2M | -53.4% | -2.61 |
| Q4 FY 2024derived | 2024-12-31 | $103.3M | -$59.4M | -57.5% | n/a |
| Q3 FY 2024 | 2024-09-30 | $62.2M | -$107.0M | -172.0% | -4.92 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $958.4M | -$288.3M | -$189.6M | $467K | n/a | n/a |
| FY 2024 | 2024-12-31 | $180.1M | -$465.9M | -$455.6M | $1.5M | n/a | n/a |
| FY 2023 | 2023-12-31 | $0 | -$373.6M | -$324.2M | $1.5M | n/a | n/a |
| FY 2022 | 2022-12-31 | $0 | -$295.4M | -$224.9M | $217K | n/a | n/a |
| FY 2021 | 2021-12-31 | $0 | -$241.8M | -$183.9M | $209K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Madrigal Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Madrigal Pharmaceuticals (MDGL), SEC CIK 1157601, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-15.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-28.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1157601Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of MDGL is sold short?
2,194,545 shares were held short at the 2026-10-15 settlement, 7.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MDGL's daily short volume?
On 2026-10-28, 40,853 of the 124,727 MDGL shares reported to FINRA were sold short, 32.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MDGL have fails to deliver?
The SEC's latest file shows 3 MDGL shares failed to deliver at settlement 2026-09-15. Fails are reported per settlement date and published twice a month with a lag.
Are MDGL insiders buying or selling?
Insiders at MDGL reported 25 open-market sells worth $6.6M in the last 90 days and no open-market buys. Latest filing: Sibold William John (President and CEO) on 2026-09-11.
Have MDGL insiders filed to sell?
26 Form 144 notices on file for MDGL worth $102.7M at the prices reported; 2 in the last 90 days worth $28.6M. Latest: PAUL FRIEDMAN filed on 2026-09-28 to sell 50,000 shares ($25.8M) from 2026-09-28.
Who owns 5% or more of MDGL?
4 holders report 5% or more of MDGL in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is JANUS HENDERSON GROUP PLC at 8.8% of the class (2,018,647 shares), filed 2026-05-15 for an event on 2026-03-31.
What did MDGL report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Madrigal Pharmaceuticals reported revenue of $364.3M, up 71.2% from the same quarter a year earlier, and net loss of $57.9M (-1.99 diluted EPS). In FY 2025 it generated -$189.6M of operating cash flow. As of 2026-06-30, cash was $292.7M against $340.8M of debt.
Which tracked 13F managers own MDGL?
8 of the 30 tracked 13F managers held MDGL shares at their latest filing, $1.16B in all. The largest: John Paulson's Paulson & Co. (1.3M shares, $719.5M), Ken Griffin's Citadel Advisors (507K shares, $272.4M), Steve Cohen's Point72 Asset Management (137K shares, $73.6M), Izzy Englander's Millennium Management (81K shares, $43.6M), Renaissance Technologies (46K shares, $24.7M), D. E. Shaw & Co. (35K shares, $18.8M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.